<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530269</url>
  </required_header>
  <id_info>
    <org_study_id>AMIC-AC-002</org_study_id>
    <nct_id>NCT01530269</nct_id>
  </id_info>
  <brief_title>C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma</brief_title>
  <official_title>C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phoenix Molecular Imaging</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phoenix Molecular Imaging</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant
      metastases from prostate cancer. This clinical trial is studying how this imaging test may
      help influence the choice and extent of initial treatments, and subsequent treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the role of positron emission tomography using carbon-11 acetate (AC-PET) in
           the initial and subsequent management of patients with prostate cancer at intermediate
           or high risk for recurrence after initial curative therapy.

        -  Compare the value of AC-PET in predicting recurrence of prostate cancer with that of
           conventional approaches (e.g., pre-operative clinical staging, prostate-specific
           antigen, Gleason score, prostate and lymph node histology) in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue Biopsy of metastatic site(s)</measure>
    <time_frame>Assessed within 30 days following AC-PET</time_frame>
    <description>Patients will undergo needle biopsy of positive metastatic findings on C11- Acetate PET/CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA (prostate specific antigen)</measure>
    <time_frame>Each 3 - 6 months for 24 months</time_frame>
    <description>PSA (prostate specific antigen) will be monitored per routine clinical follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>PET/CT imaging with C11-Sodium Acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C11-Sodium Acetate</intervention_name>
    <description>PET Imaging with C11-Sodium Acetate</description>
    <arm_group_label>PET/CT imaging with C11-Sodium Acetate</arm_group_label>
    <other_name>C11 Acetate PET</other_name>
    <other_name>Carbon 11</other_name>
    <other_name>AC-PET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male patients will be studied who have prostate cancer:

          -  Diagnosed with prostate adenocarcinoma

          -  Has completed conventional staging examinations, including histologic evaluation with
             Gleason score, CT scan of the abdomen and pelvis, and whole-body bone scintigraphy
             Candidate for curative prostatectomy OR curative radiotherapy OR staging
             lymphadenectomy prior to surgery

          -  Deemed to be at intermediate or high risk for recurrence or metastatic disease after
             initial curative treatment, as defined by of one of the following:

               -  Gleason score &gt;= 7 or PSA &gt;= 10

               -  Gleason score &lt; 7 or PSA &lt;10 ng/mL with positive surgical margins, biopsy proven
                  or suspected regional nodal involvement or conventional imaging showing limited
                  metastatic disease that may be amenable to directed radiotherapy

               -  Rising or non-responding PSA

        Exclusion Criteria:

          -  &lt; 18 years old

          -  claustrophobic patients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Almeida, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Director, Phoenix Molecular Imaging</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabio Almeida, MD</last_name>
    <phone>520-661-5125</phone>
    <email>falmeida@phxmi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisa Blackwell, CRC</last_name>
    <email>eblackwell@phxmi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Molecular Imaging</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Almeida, MD</last_name>
      <phone>520-661-5125</phone>
      <email>falmeida@phxmi.com</email>
    </contact>
    <investigator>
      <last_name>Fabio Almeida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Phoenix Molecular Imaging</investigator_affiliation>
    <investigator_full_name>Fabio Almeida MD</investigator_full_name>
    <investigator_title>Medical Director and Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>intermediate</keyword>
  <keyword>high</keyword>
  <keyword>risk</keyword>
  <keyword>radiation</keyword>
  <keyword>therapy</keyword>
  <keyword>planning</keyword>
  <keyword>surgical</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

